A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy
Tendinopathy
About this trial
This is an interventional basic science trial for Tendinopathy focused on measuring patellar tendinopathy, somatropin, jumper's knee
Eligibility Criteria
Inclusion Criteria:
- Males and females ages 18 - 50
- Patients with a greater than 3 month history of anterior knee pain
- Patients with a confirmed diagnosis of patellar tendinopathy (confirmation by ultrasonography demonstrating local anterior-posterior thickening of the tendon of at least 1mm compared with the mid-tendon level, and a hypo-echoic area)
Exclusion Criteria:
- Patients who have received corticosteroid injections within 12 months
- Patients who have full-width disruptions of the patellar tendon
- Patients who have undergone previous knee surgery or intraarticular injury
- Patients who have have arthritis (Kellgren and Lawrence grade 2 or higher), open growth plates, diabetes, cardiovascular disease, history of cancer or any major medical illnesses or endocrine disorders
- Patients with a body mass index greater than 35
- Women who are pregnant or planning to become pregnant
- Patients who are current collegiate, professional or elite athletes, or are participating in sports organizations that currently ban the use of somatropin
Sites / Locations
- Hospital for Special Surgery
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Drug: Somatropin
Drug: Placebo
Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.